Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A critical analysis of the REWIND cardiovascular outcomes trial for dulaglutide, covering enrollment biases, generalizability gaps, statistical nuances, and post-publication commentary.
Read clinical reviewHow much does dulaglutide's 12% MACE reduction actually cost per QALY? A deep dive into the health-economic analyses built on REWIND, payer-coverage realities, and the value calculation for patients with type 2 diabetes.
Read clinical reviewDeep dive into the REWIND trial's post-trial follow-up, durability of dulaglutide's cardiovascular benefit, long-term safety signals, and what extended observation revealed beyond the original 5.4-year median.
Read clinical reviewA deep dive into the REWIND trial's primary and secondary endpoint results for dulaglutide 1.5 mg in type 2 diabetes, including MACE effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
Read clinical reviewA plain-English deep dive into the REWIND cardiovascular outcomes trial for dulaglutide (Trulicity) in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
Read clinical reviewA deep dive into the REWIND trial's 12% MACE reduction with dulaglutide and what it means for real-world prescribing in type 2 diabetes, including guideline updates, patient selection, and primary prevention implications.
Read clinical review